Net Margin

6.7%
Current
Declining
by 2.4%
vs 3-y average of 9.1%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.7%
=
Net Income
kr1.5B
/
Revenue
kr23B

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
6.7%
=
Net Income
$1.5B
/
Revenue
kr23B

Peer Comparison

Country Company Market Cap Net
Margin
DK
Demant A/S
CSE:DEMANT
41.5B DKK
Loading...
US
Abbott Laboratories
NYSE:ABT
199.8B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
176.1B USD
Loading...
US
Stryker Corp
NYSE:SYK
148.2B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
124.9B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
112.5B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
46.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
51B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
49.5B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
50.2B USD
Loading...
US
GE Healthcare Technologies Inc
NASDAQ:GEHC
38.4B USD
Loading...

Market Distribution

In line with most companies in Denmark
Percentile
54rd
Based on 559 companies
54rd percentile
6.7%
Low
-18 280.1% — 1.4%
Typical Range
1.4% — 15.8%
High
15.8% — 2 389.6%
Distribution Statistics
Denmark
Min -18 280.1%
30th Percentile 1.4%
Median 3.9%
70th Percentile 15.8%
Max 2 389.6%

Demant A/S
Glance View

Demant A/S, an eminent player in the world of hearing healthcare, finds its roots in Denmark, where it was founded in 1904. The journey, sparked by the compassion of founder Hans Demant who sought ways to improve his wife's hearing experience, has evolved into a global operation focused on improving quality of life through innovative hearing solutions. Demant transcends beyond traditional hearing aids, carving a niche in providing a broad range of hearing healthcare services. These include audiometric equipment, hearing implants, diagnostic instruments, and personal communication applications, all aligned with the mission to help people overcome communication barriers. Key to Demant's strategy is its strong emphasis on research and development, ensuring that it remains at the forefront of technological advancements in audiology. The company monetizes its operations through a combination of cutting-edge product sales and a suite of ancillary services that cater to different segments of the hearing healthcare market. Leveraging a robust distribution network, Demant ensures a wide market reach, with offerings meticulously tailored to meet regional consumer needs. Collaborations with retailers, hospitals, and clinics across the globe amplify its market penetration, driving both revenue and brand loyalty. Additionally, Demant taps into the growing demand for auditory digital health solutions, offering cloud-based services that integrate seamlessly into consumer lifestyles. This multifaceted approach not only diversifies revenue streams but also fortifies Demant's standing as a holistic hearing solutions provider, underpinned by a commitment to enhancing living through auditory wellness.

WILYY Intrinsic Value
26.47 USD
Undervaluation 48%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
6.7%
=
Net Income
kr1.5B
/
Revenue
kr23B
What is Demant A/S's current Net Margin?

The current Net Margin for Demant A/S is 6.7%, which is below its 3-year median of 9.1%.

How has Net Margin changed over time?

Over the last 3 years, Demant A/S’s Net Margin has decreased from 10.6% to 6.7%. During this period, it reached a low of 6.7% on Jan 31, 2026 and a high of 11% on Jun 30, 2024.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett